Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 16/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 16/20 | 0.38 |
| ▸ | PDE1A | P54750 | 15/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27186188 | 0.86 | NPC1 (0.34) | NPC1 | |
| SCHEMBL27186184 | 0.86 | NPC1 (0.34) | NPC1 | |
| SCHEMBL27186115 | 0.85 | JAK1 (0.34) | NPC1 | |
| SCHEMBL29844258 | 0.84 | DGAT1 (0.36) | PDE1BPDE1CPDE1ANPC1 | |
| SCHEMBL27186166 | 0.80 | PDE1A (0.32) | PDE1BPDE1CPDE1APDE4D | |
| SCHEMBL27186123 | 0.76 | PDE4B (0.35) | PDE1BPDE1CPDE1A | |
| SCHEMBL27185463 | 0.69 | NPC1 (0.35) | NPC1 | |
| SCHEMBL29966986 | 0.69 | DGAT1 (0.35) | NPC1 | |
| SCHEMBL19616675 | 0.68 | DGAT1 (0.37) | NPC1 | |
| SCHEMBL20753970 | 0.68 | NPC1 (0.38) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2022187266-A1 | NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | PDE1B 1585/4885PDE1C 1979/4885PDE1A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.